Image source: Getty Images.What: Shares of Celator Pharmaceuticals (NASDAQ: CPXX), a clinical-stage oncology-focused biopharmaceutical company, have rocketed 1,610% higher year to date, according to data from S&P Global Market Intelligence. Stellar data from a candidate aimed at an underserved population, and subsequent acquisition by Jazz Pharmaceuticals (NASDAQ: JAZZ) launched this biotech into orbit.Continue reading